HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## : ESMO-MCBS Evaluation Form - JSON Representation

Active as of 2026-05-21

Raw json | Download

    {
      "resourceType" : "CodeSystem",
      "id" : "sact-esmo-mcbs-evaluation-form",
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem sact-esmo-mcbs-evaluation-form</b></p><a name=\"sact-esmo-mcbs-evaluation-form\"> </a><a name=\"hcsact-esmo-mcbs-evaluation-form\"> </a><p>This  code system <code>https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">ST-1a<a name=\"sact-esmo-mcbs-evaluation-form-ST-1a\"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies</td></tr><tr><td style=\"white-space:nowrap\">ST-1b<a name=\"sact-esmo-mcbs-evaluation-form-ST-1b\"> </a></td><td>Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting</td></tr><tr><td style=\"white-space:nowrap\">ST-2a<a name=\"sact-esmo-mcbs-evaluation-form-ST-2a\"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style=\"white-space:nowrap\">ST-2b<a name=\"sact-esmo-mcbs-evaluation-form-ST-2b\"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style=\"white-space:nowrap\">ST-2c<a name=\"sact-esmo-mcbs-evaluation-form-ST-2c\"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style=\"white-space:nowrap\">ST-3<a name=\"sact-esmo-mcbs-evaluation-form-ST-3\"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr><tr><td style=\"white-space:nowrap\">HM-1a<a name=\"sact-esmo-mcbs-evaluation-form-HM-1a\"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies</td></tr><tr><td style=\"white-space:nowrap\">HM-1b<a name=\"sact-esmo-mcbs-evaluation-form-HM-1b\"> </a></td><td>Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies</td></tr><tr><td style=\"white-space:nowrap\">HM-2a<a name=\"sact-esmo-mcbs-evaluation-form-HM-2a\"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style=\"white-space:nowrap\">HM-2b<a name=\"sact-esmo-mcbs-evaluation-form-HM-2b\"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style=\"white-space:nowrap\">HM-2c<a name=\"sact-esmo-mcbs-evaluation-form-HM-2c\"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style=\"white-space:nowrap\">HM-3<a name=\"sact-esmo-mcbs-evaluation-form-HM-3\"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr></table></div>"
      },
      "url" : "https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form",
      "version" : "0.1.0",
      "name" : "EsmoMcbsEvaluationForm",
      "title" : "ESMO-MCBS Evaluation Form",
      "status" : "active",
      "date" : "2026-05-21T02:29:02+00:00",
      "publisher" : "Te Aho o Te Kahu, Cancer Control Agency",
      "description" : "The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale",
      "content" : "complete",
      "count" : 12,
      "concept" : [
        {
          "code" : "ST-1a",
          "display" : "Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies"
        },
        {
          "code" : "ST-1b",
          "display" : "Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting"
        },
        {
          "code" : "ST-2a",
          "display" : "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"
        },
        {
          "code" : "ST-2b",
          "display" : "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"
        },
        {
          "code" : "ST-2c",
          "display" : "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"
        },
        {
          "code" : "ST-3",
          "display" : "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"
        },
        {
          "code" : "HM-1a",
          "display" : "Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies"
        },
        {
          "code" : "HM-1b",
          "display" : "Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies"
        },
        {
          "code" : "HM-2a",
          "display" : "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"
        },
        {
          "code" : "HM-2b",
          "display" : "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"
        },
        {
          "code" : "HM-2c",
          "display" : "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"
        },
        {
          "code" : "HM-3",
          "display" : "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"
        }
      ]
    }